Pediatric toxic epidermal necrolysis treated successfully with infliximab

Research output: Contribution to journalJournal articleResearchpeer-review

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.

Original languageEnglish
JournalPediatric Dermatology
Volume36
Issue number3
Pages (from-to)342-345
Number of pages4
ISSN0736-8046
DOIs
Publication statusPublished - 2019

    Research areas

  • infliximab, mycoplasma pneumoniae, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxic epidermal necrolysis, alpha inhibitor

ID: 226414562